Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fazpilodemab - Genentech

Next Previous
Drug Profile

Fazpilodemab - Genentech

Alternative Names: BFKB-8488A; RG 7992; RO 7040551

Latest Information Update: 05 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antihyperglycaemics; Bispecific antibodies; Hepatoprotectants; Insulin sensitisers
  • Mechanism of Action KLB protein inhibitors; Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 10 Nov 2023 Genentech terminates the phase II BANFF trial in Non-alcoholic steatohepatitis in USA, Belgium, France, Puerto Rico and Spain due to strategic business reason (SC) (NCT04171765) (EudraCT2019-001897-27)
  • 10 Nov 2023 Efficacy and adverse event data from the phase II BANFF trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 28 Oct 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Canada (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top